Table 4. Statistical values of all metrics for differentiating between lung cancers and benign lesions and NSCLC and SCLC.
| Metrics | AUC | P Value | Sensitivity | Specificity |
|---|---|---|---|---|
| Lung cancers VS Benign lesions | ||||
| CEA | 0.769 | <0.001a | 76.92% | 65.63% |
| CYFRA21-1 | 0.744 | <0.001a | 40.83% | 100.00% |
| SCC-Ag | 0.641 | 0.012a | 40.83% | 84.38% |
| NSE | 0.756 | <0.001a | 76.33% | 68.75% |
| SUVmax | 0.767 | <0.001a | 88.76% | 59.38% |
| Combined tumor markers | 0.871 | <0.001a | 66.86% | 93.75% |
| SUVmax+Tumor markers | 0.902 | <0.001a | 84.02% | 87.50% |
| NSCLC VS SCLC | ||||
| CEA | 0.603 | 0.037a | 50.00% | 70.25% |
| CYFRA21-1 | 0.623 | 0.013a | 72.92% | 51.24% |
| SCC-Ag | 0.600 | 0.043a | 56.25% | 62.81% |
| NSE | 0.805 | <0.001a | 60.42% | 90.08% |
| SUVmax | 0.559 | 0.229 | 75.00% | 44.63% |
| Combined tumor markers | 0.911 | <0.001a | 75.00% | 92.56% |
| SUVmax+Tumor markers | 0.916 | <0.001a | 87.50% | 84.30% |
a P<0.05.
AUC: area under the curve; CEA: carcino embryonie antigen, CYFRA21-1: cytokeratin 19 fragments, SCC-Ag: squmaous cell carcinoma antigen, NSE: neuron specific enolase, SUVmax: maximal standard uptake value, SCLC: small-cell lung carcinoma, NSCLC: non-small-cell lung carcinoma.